Healthcare industry - add the P to ESG
Ondine Bennaïm
Medtech and Life Sciences Regulatory and Quality Executive Leadership - Digital health literacy - Board Member - Women's Health
Environmental and sustainability talks are at an all time high, globally. If only 5 -10 years ago, ESG efforts were still mainly declarative and voluntary, given as side-jobs to high performers, nowadays, corporations have included ESG in their quarterly and financial reports, have specific KPIs to track the transition to environmental goals and even make ESG part of recruitment campaigns, showing environmentally conscious workforce that they are serious about sustainability and long term planet preservation.
Through Cerebris , I am making now a plea to pharmaceutical and medtech industries - add P (prevention) to your ESG efforts. Contribute actively to prevention of chronic conditions through allocation of R&D funds focused towards prevention.
#pharma #medtech #plea #prevention #esg #morecanbedone #addtheptoesg
Global marketing & innovation | MedTech & Life Sciences | Sustainability/ESG in Business | Mountain-inspired
5moNice parralel and article Ondina Bennaïm Similitudes definitely exist between the two topics. 1) like for ESG, the need to show allocating budget to prevention would yield direct/indirect financial returns for companies is key 2) like for ESG, incentives/triggers may come from different market souces and most likely a mix of them (investors, think tanks, public opinion/customers, employees, public powers/governments) 3) like for ESG, finding like-minded allies and advocating from within industry associations may be a way to go. In the end, isn’t the « P » quietly nesteld in the depths of the « S » for pharma/medtech, given the immense positive impact it would provide society ?